131results about "Cytokeratin" patented technology

Present invention teaches the method of using a keratin hydrolysis peptide (“KHP”) solution to enhance production yield and fruit quality of cucumber by selectively choosing specific weights of feathers and water, and treating the mixture to a high-temperature high-pressure hydrolysis process, the resulting solution is confirmed to contain at least 253 peptides and, at early growth stage, applied to the soil around and / or leaf surface of the cucumber plants. Optionally, the KHP solution can be diluted by water, as disclosed in the specification, before administering as taught herein.

Present invention teaches the method of using a keratin hydrolysis peptide (“KHP”) solution to promote the growth and development of corn crops, by selectively choosing specific weights of feathers and water, and treating the mixture to a high-temperature high-pressure hydrolysis process, the resulting solution is confirmed to contain at least 253 peptides and, at seedling stage and / or early growth stage, applied to the soil around or sprayed to the young plants. Optionally, the KHP solution can be diluted by water, as disclosed in the specification, before administering as taught herein.

Present invention teaches the method of using a keratin hydrolysis peptide (“KHP”) solution to enhance sweetness and flavors of tea leaves. By selectively choosing specific weights of feathers and water, and treating the mixture to a high-temperature high-pressure hydrolysis process, the resulting solution is confirmed to contain at least 253 peptides and then applied to the surface of tea leaves during sprouting stage and infused to the soil around the tea trees / plants; the increased content of L-theanine and polyphenol is separately tested and confirmed. Optionally, the KHP solution can be diluted by water, as taught in the specification, before applying to the tea leaves and the soil as taught herein.

Present invention teaches the method of using a keratin hydrolysis peptide (“KHP”) solution to enhance the drought tolerance attribute of wheat plants. By selectively choosing specific weights of feathers and water, and treating the mixture to a high-temperature high-pressure hydrolysis process, the resulting solution is confirmed to contain at least 253 peptides and then infused to the soil in which the wheat seeds are planted; the solution can also be sprayed to the leaf surface of young wheat plants. Optionally, the KHP solution can be diluted by water, as disclosed in the specification, for applying to the soil around the wheat plants and for spraying to leaf surface of young wheat plants.

Present invention teaches the method of using a keratin hydrolysis peptide (“KHP”) solution to improve the efficacy of fertilizer usage and absorption by soybeans. By selectively choosing specific weights of feathers and water, and treating the mixture to a high-temperature high-pressure hydrolysis process, the resulting solution is confirmed to contain at least 253 peptides and then infused to the fertilized soil in which the soybean seeds are grown, as well as the plants after the seed start sprouting. Optionally, the KHP solution can be diluted by water, as disclosed in the specification, for applying to the soil around the soybean.

Present invention teaches the method of using a keratin hydrolysis peptide (“KHP”) solution to improve the efficacy of fertilizer usage and absorption by soybeans. By selectively choosing specific weights of feathers and water, and treating the mixture to a high-temperature high-pressure hydrolysis process, the resulting solution is confirmed to contain at least 253 peptides and then infused to the fertilized soil in which the soybean seeds are grown, as well as the plants after the seed start sprouting. Optionally, the KHP solution can be diluted by water, as disclosed in the specification, for applying to the soil around the soybean.

The present application provides a keratin and a nucleic acid sequence encoding the same. The present application further provides a keratin gel dressing comprising the keratin of the present application, bFGF and a gel matrix.

The invention provides transdermal recombinant keratin as well as a preparation method and application thereof, and relates to the technical field of genetic engineering. The transdermal recombinant keratin comprises a recombinant keratin and a cell penetrating peptide; the transdermal recombinant keratin has cell adhesion activity and transdermal property. The transdermal recombinant keratin comprises any one amino acid sequence as shown in SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3 and SEQ ID NO.4 or consists of the amino acid sequence as shown in SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3 and SEQ ID NO.4. According to the transdermal recombinant keratin, the transdermal performance and the cell adhesion activity of keratin are remarkably improved, and the problem that traditional recombinant keratin is poor in skin permeability is solved.

The invention belongs to the field of biological pharmacy, and provides keratin YK93-4, a coding nucleic acid molecule thereof, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, and a preparation method and a pharmaceutical composition of the keratin YK93-4. The invention also provides application of the keratin YK93-4 and related products thereof in preparation of medicines for treating lung cancer, lymphoma, breast cancer, melanoma, hysteromyoma, benign prostatic hyperplasia and the like.

Relates to the technical field of medicines, provides keratin CF5, a preparation method, a pharmaceutical composition and application thereof, and particularly relates to keratin CF5, a nucleic acid molecule for coding the keratin CF5, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, and a preparation method of the keratin CF5. The invention relates to a keratin CF5-containing pharmaceutical composition and application of the keratin CF5, nucleic acid molecules, expression vectors, host cells or the pharmaceutical composition in preparation of antipyretic and analgesic, cough-relieving and phlegm-eliminating drugs, anticonvulsion, antiepilepsy, blood pressure lowering drugs, anti-inflammatory drugs and antiviral drugs, in particular to application of the keratin CF5, the nucleic acid molecules, the expression vectors, the host cells or the pharmaceutical composition in preparation of antipyretic and analgesic drugs.

Belongs to the technical field of medicine, and provides keratin CF7, a preparation method, a pharmaceutical composition and application thereof. Specifically, the invention provides keratin CF7, a nucleic acid molecule encoding the keratin CF7, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, a preparation method of the keratin CF7, a pharmaceutical composition containing the keratin CF7, and a preparation method of the keratin CF7. The invention also discloses application of the keratin CF7, the nucleic acid molecule, the expression vector, the host cell or the pharmaceutical composition in preparation of antipyretic and analgesic, cough-relieving and phlegm-eliminating, anti-convulsion, anti-epilepsy, antihypertensive, anti-inflammatory and antiviral drugs.

The invention provides keratin CF3 as well as a preparation method, a pharmaceutical composition and application thereof, and belongs to the technical field of medicines. Specifically, the invention provides keratin CF3, a nucleic acid molecule encoding the keratin CF3, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, a preparation method of the keratin CF3, a pharmaceutical composition containing the keratin CF3, and a preparation method of the keratin CF3. The invention also discloses application of the keratin CF3, the nucleic acid molecule, the expression vector, the host cell or the pharmaceutical composition in preparation of antipyretic and analgesic drugs, antitussive and expectorant drugs, anticonvulsion drugs, antiepileptic drugs, antihypertensive drugs, anti-inflammatory drugs and antiviral drugs.

The invention provides keratin CF4 as well as a preparation method, a pharmaceutical composition and application thereof, and belongs to the technical field of medicines. Specifically, the invention provides keratin CF4, a nucleic acid molecule encoding the keratin CF4, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, a preparation method of the keratin CF4, a pharmaceutical composition containing the keratin CF4, and a preparation method of the keratin CF4. The invention also discloses application of the keratin CF4, the nucleic acid molecule, the expression vector, the host cell or the pharmaceutical composition in preparation of antipyretic and analgesic drugs, antitussive and expectorant drugs, anticonvulsion drugs, antiepileptic drugs, antihypertensive drugs, anti-inflammatory drugs and antiviral drugs.

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-6, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-6 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, analgesia, lactation, breast cancer, lung cancer, uterine fibroids, coagulation, etc.

The invention belongs to the field of biological pharmacy, and provides keratin YK93-5, a coding nucleic acid molecule thereof, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, and a preparation method and a pharmaceutical composition of the keratin YK93-5. The invention also provides application of the keratin YK93-5 and other products in preparation of drugs for treating lung cancer, lymphoma, breast cancer, melanoma, hysteromyoma, prostatic hyperplasia and the like.

Belongs to the technical field of medicines, and relates to keratin CF1, a preparation method, a pharmaceutical composition and application thereof, in particular to keratin CF1, a nucleic acid molecule for encoding keratin CFI, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, and a preparation method of the keratin CF1. The invention relates to a keratin CF1-containing pharmaceutical composition and application of the keratin CF1, nucleic acid molecules, expression vectors, host cells or the pharmaceutical composition in preparation of antipyretic and analgesic, cough-relieving and phlegm-eliminating drugs, anticonvulsion, antiepilepsy, blood pressure lowering drugs, anti-inflammatory drugs and antiviral drugs, in particular to application of the keratin CF1, the nucleic acid molecules, the expression vectors, the host cells or the pharmaceutical composition in preparation of antipyretic and analgesic drugs.

Belongs to the technical field of medicines, discloses keratin CF2, a preparation method, a pharmaceutical composition and application thereof, and particularly relates to keratin CF2, a nucleic acid molecule for encoding the keratin CF2, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, and a preparation method of the keratin CF2. The invention relates to a keratin CF2-containing pharmaceutical composition and application of the keratin CF2, nucleic acid molecules, expression vectors, host cells or the pharmaceutical composition in preparation of antipyretic and analgesic, cough-relieving and phlegm-eliminating drugs, anticonvulsion, antiepilepsy, blood pressure lowering drugs, anti-inflammatory drugs and antiviral drugs, in particular to application of the keratin CF2, the nucleic acid molecules, the expression vectors, the host cells or the pharmaceutical composition in preparation of antipyretic and analgesic drugs.

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-8, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-8 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, breast cancer, lung cancer, analgesia, lactation, uterine fibroids, coagulation, etc.

Belongs to the technical field of medicine, and provides keratin CF8, a preparation method, a pharmaceutical composition and application thereof. Provided are a keratin CF8, a nucleic acid molecule encoding the keratin CF8, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, a preparation method of the keratin CF8, and a pharmaceutical composition containing the keratin CF8. The invention also discloses application of the keratin CF8, the nucleic acid molecule, the expression vector, the host cell or the pharmaceutical composition in preparation of antipyretic and analgesic, cough-relieving and phlegm-eliminating, anti-convulsion, anti-epilepsy, antihypertensive, anti-inflammatory and antiviral drugs.

The present invention provides a keratin BD-13, an encoding nucleic acid molecule, an expression vector, a host cell, a preparation method thereof, and a pharmaceutical composition containing the keratin. The keratin BD-13 can be used in the preparation of medicamnet for antipyretic, analgesic, antitussive, expectorant, anticonvulsant, antiepileptic, anti-hypertension, anti-inflammatory, and antiviral.

The present invention concerns enriched heterogenerous mammalian renal cell populations characterized by biomarkers, and methods of making and using the same.

The invention belongs to the technical field of medicines, and relates to keratin CF6, a preparation method, a pharmaceutical composition and application thereof. In particular to keratin CF6, a nucleic acid molecule for coding the keratin CF6, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, a preparation method of the keratin CF6 and a pharmaceutical composition containing the keratin CF6. The invention also discloses application of the keratin CF6, the nucleic acid molecule, the expression vector, the host cell or the pharmaceutical composition in preparation of antipyretic and analgesic drugs, antitussive and expectorant drugs, anticonvulsion drugs, antiepileptic drugs, antihypertensive drugs, anti-inflammatory drugs and antiviral drugs.

The present application relates to keratin protein extracts, compositions, methods and uses thereof. In some embodiments, the keratin protein extract is a beta-keratin extract. In some embodiments, the compositions are beta-keratin compositions. In some embodiments, the methods are methods of cleaning a keratin source material, methods of extracting beta-keratin, methods of preparing keratin compositions, and methods of using keratin protein extracts and compositions.

The invention belongs to the technical field of medicines, and relates to keratin CF12, a preparation method, a pharmaceutical composition and application thereof. Relates to a keratin CF12, a nucleic acid molecule for coding the keratin CF12, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, a preparation method of the keratin CF12, and a pharmaceutical composition containing the keratin CF12. The invention also discloses application of the keratin CF12, the nucleic acid molecule, the expression vector, the host cell or the pharmaceutical composition in preparation of antipyretic and analgesic drugs, antitussive and expectorant drugs, anticonvulsion drugs, antiepileptic drugs, antihypertensive drugs, anti-inflammatory drugs and antiviral drugs.

The invention relates to the field of keratin extraction methods. More particularly, the invention relates to a method for extracting keratin, in particular human hair keratin, without chemical products. The method comprises three thermal hydrolysis steps. The keratin obtained is of high quality, the amino acid composition of same being close to that of native keratin, and can be used in applications with a high added value such as cosmetics or medical devices. The biomimicry between the keratin extracted from hair using this extraction method and natural keratin is more than 90%.

The present application provides a recombinant keratin. When the keratin of the present application is used for wound repair, the repair function is greatly improved, especially for the repair of chronic wounds such as diabetic foot ulcers, bedsores, and venous ulcers. It accelerates the formation of new granulation and epithelial tissue during the granulation proliferation stage and epithelial formation stage, can quickly promote wound healing, promote wound repair, and has hemostatic and anti-inflammatory functions.

The present invention relates to citrullinated Cytokeratin peptides that can be used in cancer immunotherapy. The modified peptides may be used as vaccines or as targets for T cell receptor (TCR) and adoptive T cell transfer therapies. Such vaccines or targets may be used in the treatment of cancer.

The invention provides a KRT31 gene knockout cell line and application of the KRT31 gene knockout cell line in promotion of small RNA viridae virus replication and / or production of small RNA viridae virus vaccines, and belongs to the technical field of gene engineering. The invention provides an application of a KRT31 gene or an encoded protein thereof as a target spot in preparation of a product for regulating and controlling virus replication of a small RNA viridae and / or vaccine production. The up-regulation of the expression level of the KRT31 gene can inhibit the virus replication of the small RNA viridae, and the reduction of the expression level of the KRT31 gene can promote the virus replication of the small RNA viridae. According to the invention, the sgRNA knockout KRT31 gene is adopted to prepare a cell line with lost gene coding protein function, so that the replication of small RNA viridae viruses is promoted, the virus titer and the antigen yield are improved, and the efficient preparation of small RNA viridae virus vaccines is facilitated.

The invention belongs to the field of biological pharmacy, and provides keratin YK93-9, a coding nucleic acid molecule thereof, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, and a preparation method and a pharmaceutical composition of the keratin YK93-9. The invention also provides application of the keratin YK93-9 and other substances in preparation of medicines for treating lung cancer, lymphoma, breast cancer, melanoma, hysteromyoma, prostatic hyperplasia and the like.